Z Squared Inc. quarterly report, Q3 FY2023

Filing summary: Coeptis Therapeutics Holdings, Inc. — Q3 2023 Form 10-Q

Registrant note: The supplied filing is for Coeptis Therapeutics Holdings, Inc., not Z Squared Inc. It covers the quarter and nine months ended September 30, 2023.

Business context and reporting period

Coeptis is a development-stage pharmaceutical and biotechnology company focused on product development and strategic partnerships in oncology and immune-cell therapies. Its portfolio includes CD38-GEAR-NK and CD38-Diagnostic, SNAP-CAR technologies, and assets licensed or acquired from Deverra Therapeutics. The filing reports unaudited consolidated results; management cautions that interim results may not indicate full-year performance.

Key financial metrics

MetricQ3 2023 / September 30, 2023Comparable period / December 31, 2022
Revenue$0 for the quarter and first nine months$0 in the 2022 comparable periods
Net loss$6.26 million for Q3; $17.24 million for nine months$5.65 million for Q3 2022; $34.63 million for nine months 2022
Operating expenses$7.83 million for Q3; $17.95 million for nine months$5.57 million for Q3 2022; $31.15 million for nine months 2022
Cash and cash equivalents$1.41 million$3.79 million at December 31, 2022
Current assets / current liabilities$4.12 million / $1.62 million$3.94 million / $1.82 million at December 31, 2022
Total notes payable$975,000, including $825,000 current—
Cash flow from operations$(5.55) million for the first nine months$(3.03) million for the first nine months of 2022
Common shares outstanding32,991,036 at September 30; 34,108,036 at November 819,566,839 at December 31, 2022

There was no revenue or gross profit, so a gross margin is not meaningful. Cash used in investing activities was zero. Financing activities provided $3.17 million net during the first nine months of 2023. No income tax expense or benefit was recorded.

Material changes versus prior periods

  • Q3 operating expenses rose to $7.83 million from $5.57 million, primarily reflecting research and development expense associated with the Deverra transaction. R&D expense was $4.98 million in Q3 2023 versus $20,887 in Q3 2022.
  • Nine-month operating expenses fell to $17.95 million from $31.15 million, mainly because of lower professional-services costs related to equity transactions. Nine-month G&A decreased to $12.46 million from $30.95 million.
  • Nine-month net loss narrowed year over year, while Q3 net loss increased. A $1.61 million Q3 gain from the change in fair value of warrant liabilities partially offset the quarterly loss; the warrant liability was $378,375 at period-end.
  • Cash declined by $2.38 million from year-end 2022. Operating cash use increased year over year, despite the lower reported nine-month net loss.
  • Common shares outstanding increased substantially during 2023, including from equity issuances, shares issued for services and the Deverra asset purchase.

Outlook, risks, contingencies and unusual items

  • Going concern: The company reported an accumulated deficit of $82.98 million and stated that substantial doubt exists about its ability to continue as a going concern. Management expects to seek additional equity or debt financing; there is no assurance it will be available or that operations will become profitable.
  • Revenue outlook: Management does not expect significant revenue for at least the next two years while it pursues development and commercialization, potentially with partners. It expects R&D and public-company operating costs to increase.
  • Deverra transaction: In August 2023, Coeptis acquired and licensed assets, including two IND applications and two Phase 1 programs. Consideration totaled approximately $4.94 million, including cash and 4 million shares, and was expensed as R&D. The filing also describes contingent royalties, milestones and assumed trial-related liabilities. A six-month shared-services agreement followed in October.
  • Financing and dilution: A June public offering generated approximately $3.0 million net. After quarter-end, an October private placement generated approximately $1.78 million net and included shares and warrants. The October transaction also repriced the June Series Warrants from $1.65 to $1.36 per share. These subsequent proceeds are not included in September 30 cash.
  • Debt: A $200,000 note due June 15, 2023 was unpaid and in default at quarter-end; the company reported a verbal understanding to convert the principal to equity. The Purple BioTech convertible note had $625,000 outstanding, with an amended outside maturity date of March 31, 2024. The filing reports $975,000 total notes payable.
  • Receivables: The balance sheet includes $2.5 million of notes receivable. The notes describe two September transactions for $500,000 and $2 million, bearing 6% interest and due August 30, 2024, with shares issued in connection with the notes. The structure and collectability merit review.
  • Development portfolio: FDA classified CD38-Diagnostic as a Class II device in September 2023. Coeptis terminated the remaining University of Pittsburgh option agreement in October 2023; a separate SNAP-CAR license remained described in the filing.
  • Controls and legal matters: Management said disclosure controls were effective at September 30 and believed internal controls were operating effectively after remedial actions. The filing also references a material weakness in internal control over financial reporting at December 31, 2022, involving inadequate segregation of duties. The company reported no material litigation.

Most important facts for investors to verify

  • Whether the company can raise sufficient capital to fund operations, and the expected cash runway given $1.41 million of quarter-end cash and $5.55 million of nine-month operating cash use.
  • The terms, counterparties, accounting and recoverability of the $2.5 million notes receivable, including the related share issuances.
  • The status and consequences of the defaulted $200,000 note and the remaining $625,000 Purple BioTech obligation.
  • The development plans, costs, milestones, liabilities and potential royalties associated with the Deverra assets and other programs.
  • The fully diluted share count and potential dilution from outstanding warrants, options and subsequent financing; the filing reports 34,108,036 common shares outstanding on November 8, 2023.
  • Whether the disclosed internal-control remediation has resolved the previously identified segregation-of-duties weakness.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.